IMNMHealthcare · BiotechnologyIMNM Stock Forecast: Immunome, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Immunome, Inc. hold a median 12-month price target of $36 — +56.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 1 Aug 2026 — in the lower half.
IMNM stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Immunome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Immunome, Inc. — and when they’d sell — is the membership.
IMNM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMNM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +56.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Wedbush | Reiterates | Outperform | $31 |
| 21 July 2026 | Wedbush | Reiterates | Outperform | — |
| 12 June 2026 | Wedbush | Reiterates | Outperform | $31 |
| 12 June 2026 | Wedbush | Reiterates | Outperform | — |
| 28 May 2026 | Barclays | Initiates | Overweight | — |
| 28 May 2026 | Truist Securities | Maintains | Buy | — |
| 15 May 2026 | Leerink Partners | Maintains | Outperform | — |
| 13 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Mar 2026 | Craig-Hallum | Maintains | Buy | — |
| 4 Mar 2026 | Stephens & Co. | Maintains | Overweight | — |
| 12 Feb 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 15 Jan 2026 | Wedbush | Reiterates | Outperform | — |
| 16 Dec 2025 | Evercore ISI Group | Maintains | Outperform | — |
| 16 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 16 Dec 2025 | Lake Street | Maintains | Buy | — |
| 1 Dec 2025 | Truist Securities | Initiates | Buy | — |
| 17 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 22 Sept 2025 | Goldman Sachs | Initiates | Buy | — |
| 5 Sept 2025 | Craig-Hallum | Initiates | Buy | — |
| 25 Aug 2025 | Guggenheim | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IMNM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Immunome, Inc. (IMNM) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −9.3×
- Price / sales
- 642.0×
- Price / book
- 4.4×
- EV / EBITDA
- −8.8×
Cheaper than 92% of US stocks
Cheaper than 2% of US stocks
Cheaper than 24% of US stocks
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −5698.8%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- −50.1%
- Return on assets
- −29.7%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IMNM vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMNM appears on the weeks it earns a place.
Frequently asked questions about IMNM stock
What is the IMNM stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Immunome, Inc. have a median 12-month price target of $36, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMNM stock a buy right now?
Of the 13 analysts covering Immunome, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunome, Inc. 49 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMNM?
As at 1 Aug 2026, Immunome, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
Will IMNM stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +56.5% from the last close, and Ticker Nerd's factor model ranks Immunome, Inc. 49 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMNM stock forecast for 2030?
No analyst covering Immunome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
How has IMNM stock performed over the past year?
Immunome, Inc. returned +117.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Immunome, Inc. do?
Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector.
About Immunome, Inc.
Immunome Inc. is a biotechnology company specializing in highly innovative research and development within the life sciences sector. The primary focus of the company is to advance immunotherapy-based cancer treatments through its proprietary discovery engine that harnesses the immune system's natural capabilities. Immunome’s approach involves leveraging its unique antigen technology to identify novel targets and develop therapeutic antibodies, aimed at enabling the body's immune response to recognize and combat cancer more effectively. This cutting-edge focus places Immunome Inc. squarely at the forefront of the biologics market, with potential applications spanning various oncology therapies. Since its inception, the company has continually explored partnerships with academic institutions and other biotech firms, enhancing collaborative efforts to propel novel findings from the laboratory to clinical trials. Immunome’s efforts contribute significantly to the pharmaceutical and healthcare industries, underscoring the growing importance of targeted therapies and personalized medicine in addressing complex medical challenges. Based in Exton, Pennsylvania, Immunome Inc. represents a key player in translating breakthrough immunological insights into tangible healthcare solutions, emphasizing robust scientific innovation in combating one of the world's most persistent health issues.
CEO Dr. Clay B. Siegall Ph.D. · 206 employees · United States · https://immunome.com